[ad_1]
Resulting from the meeting of personalized medicine, an area in which Luxembourg has funded research for more than 8 years, and the Covid-19 pandemic, the Predi-Covid cohort study aims to answer several crucial questions: who is likely to do you develop a severe form of Covid-19? What risk factors are specific to this disease? And what are the predispositions to work?
“The study aims to identify clinical, epidemiological and sociodemographic features, as well as patient and SARS-CoV-2 virus-specific biomarkers, which can help predict disease course in a given individual, depending in particular on their immune profile “, the Luxembourg Institute of Health, which coordinates the study, said in a press release.
The research team recruited SARS-CoV-2 positive patients over the age of 18, with the understanding that another related study included family members of the participants, to study transmission of the virus. The recruitment and collection of data and samples began on May 5 and is expected to last until December, however an extension is planned until June 2021.
556 study participants
The principle: the evolution of the patient’s state of health and symptoms “are monitored daily thanks to various remote digital tools, depending on whether the patients are at home or in the hospital, for 14 days from confirmation. Of the diagnosis. They are also carried out. short additional assessments every month for a year, in order to assess the potential long-term consequences of Covid-19 “.
1,406 people were contacted between May and November, 556 of whom agreed to participate in the study. Another 48 are contributing to the Predi-COVID-H (entourage of positive patients) study. A biobank has been established to study the disease and already contains 627 samples, including blood, sputum, stool, hair and swab samples. Voice recordings were also made using the CoLive LIH application used by 245 participants to identify vocal biomarkers of symptoms frequently observed in patients with Covid-19, such as respiratory syndromes, fatigue, anxiety, negative emotions related to Covid-19, which could then be used for remote monitoring of patients at home.
Initial findings were that the most common symptoms at hospitalization were fever (26.2% of participants), cough (23.3%), runny nose (12.2%), and sore throat. (10.8%), while the most common comorbidities and risk factors are smoking (18.1% of participants), asthma (5.4%), diabetes (4.7%), chronic heart disease (3.6%) and obesity (3.3%).
An interdisciplinary research consortium
“We are very satisfied with the results obtained so far. We would like to encourage all people who recently tested positive for Covid-19 to participate in the study, because the greater the number of participants, the more accurate the final results will be, “comments Markus Ollert, director of the department of infectious diseases and immunity LIH and co -Predi-COVID principal investigator. “In addition, we are now collaborating with the Center Hospitalier de Luxembourg to consider the inclusion of up to 100 Covid-19 positive children in Predi-COVID and up to 30 children from affected families in Predi-COVID-H “.
“We are very grateful to the Health Inspectorate of the Ministry of Health for their unwavering support and excellent cooperation during the study, which is the key to the success of Predi-COVID”, greets Guy Fagherazzi from LIH’s Public Health Department. co-principal investigator of Predi-COVID and first author of the publication. The protocol was recently published in a renowned international journal and will serve as the source publication to cite for all future work based on Predi-COVID data. So far, nine auxiliary projects funded by the National Research Fund or the European Commission’s Horizon 2020 program are already using data from Predi-COVID “.
Launched under the auspices of the Covid-19 Luxembourg Research Task Force, the Predi-COVID study benefits from an interdisciplinary consortium of Luxembourg research institutes, namely the LIH’s Department of Infectious Diseases and Immunity, the ‘Integrated Biobank of Luxembourg, National Laboratory of Health, University of Luxembourg, Luxembourg Center for Systemic Biomedicine, Luxembourg Hospital Center and Robert Schuman Hospitals. The study is co-financed by the Luxembourg National Research Fund and the André Losch Foundation.
[ad_2]
Source link
